Merck settles tax dispute with IRS for $2.3 billion

Share this article:
Merck has entered an agreement to settle its previously disclosed tax disputes with the Internal Revenue service for $2.3 billion. The settlement essentially brings to a close the IRS’s examination of the company for the period 1993-2001, the Whitehouse Station, NJ drugmaker said in a statement issued today. The figure of $2.3 billion will cover federal tax and net interest after deductions and penalties, Merck said. The IRS' examination of years subsequent to 2001 remains open. Merck announced in November that it faced potential tax liabilities totaling $5.58 billion from US and Canadian authorities related to disputes over accounting for past transactions.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.